SEC Form 5 · accession 0001140361-18-008551
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Dec 31, 2017
Accepted (ET)
Feb 14, 2018 · 8:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 31, 2017 | A | 162 | $69.777 | A | 57,600 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired by the reporting person on October 31, 2017, pursuant to the issuer's Employee Stock Purchase Plan.
- F2Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) include 34,078 shares reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) include 57 shares inadvertently excluded in prior reports based on a reconciliation with the Company's records.